Diabetic Gastroparesis - Pipeline Review, H2 2017

Date: August 16, 2017
Pages: 56
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D2659CAC27DEN
Leaflet:

Download PDF Leaflet

Diabetic Gastroparesis - Pipeline Review, H2 2017
Diabetic Gastroparesis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 1 and 2 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Gastroparesis - Overview
Diabetic Gastroparesis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Gastroparesis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Gastroparesis - Companies Involved in Therapeutics Development
Allergan Plc
Cempra Inc
Evoke Pharma Inc
GlaxoSmithKline Plc
Johnson & Johnson
Theravance Biopharma Inc
Diabetic Gastroparesis - Drug Profiles
camicinal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEM-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metoclopramide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
renzapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
velusetrag hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Gastroparesis - Dormant Projects
Diabetic Gastroparesis - Discontinued Products
Diabetic Gastroparesis - Product Development Milestones
Featured News & Press Releases
Aug 09, 2017: EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis
May 31, 2017: Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti
May 15, 2017: Evoke Pharma Provides Update on Gimoti
May 10, 2017: Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017
May 03, 2017: EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis
May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017
Apr 04, 2017: Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA
Mar 21, 2017: Evoke Pharmas Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017
Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial
Dec 15, 2016: Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti
Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
Sep 07, 2016: Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti
Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Gastroparesis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diabetic Gastroparesis - Pipeline by Allergan Plc, H2 2017
Diabetic Gastroparesis - Pipeline by Cempra Inc, H2 2017
Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H2 2017
Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2017
Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H2 2017
Diabetic Gastroparesis - Pipeline by Theravance Biopharma Inc, H2 2017
Diabetic Gastroparesis - Dormant Projects, H2 2017
Diabetic Gastroparesis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Diabetic Gastroparesis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Allergan Plc
Cempra Inc
Evoke Pharma Inc
GlaxoSmithKline Plc
Johnson & Johnson
Theravance Biopharma Inc
Skip to top


Gastroparesis - Pipeline Review, H1 2015 US$ 2,000.00 Feb, 2015 · 37 pages
Seek - Product Pipeline Review - 2014 US$ 1,500.00 Oct, 2014 · 42 pages

Ask Your Question

Diabetic Gastroparesis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: